Champions Oncology, Inc.
CSBR
$6.80
-$0.02-0.29%
NASDAQ
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 56.88M | 56.94M | 58.59M | 53.57M | 51.66M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.88M | 56.94M | 58.59M | 53.57M | 51.66M |
| Cost of Revenue | 29.31M | 28.39M | 28.37M | 29.60M | 28.79M |
| Gross Profit | 27.57M | 28.56M | 30.22M | 23.97M | 22.87M |
| SG&A Expenses | 17.10M | 16.89M | 16.59M | 16.95M | 17.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.87M | 52.10M | 51.87M | 53.92M | 54.69M |
| Operating Income | 3.01M | 4.85M | 6.72M | -352.00K | -3.04M |
| Income Before Tax | 2.84M | 4.63M | 6.40M | -636.00K | -3.44M |
| Income Tax Expenses | -81.00K | -74.00K | -26.00K | -38.00K | -38.00K |
| Earnings from Continuing Operations | 2.92 | 4.70 | 6.43 | -0.60 | -3.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 30.00K | -- | -- | -- | -- |
| Net Income | 2.95M | 4.70M | 6.43M | -598.00K | -3.40M |
| EBIT | 3.01M | 4.85M | 6.72M | -352.00K | -3.04M |
| EBITDA | 4.56M | 6.49M | 8.43M | 1.43M | -1.17M |
| EPS Basic | 0.22 | 0.34 | 0.47 | -0.04 | -0.25 |
| Normalized Basic EPS | 0.15 | 0.23 | 0.31 | -0.01 | -0.14 |
| EPS Diluted | 0.20 | 0.32 | 0.44 | -0.06 | -0.26 |
| Normalized Diluted EPS | 0.14 | 0.21 | 0.30 | -0.01 | -0.14 |
| Average Basic Shares Outstanding | 54.84M | 54.64M | 54.48M | 54.38M | 54.28M |
| Average Diluted Shares Outstanding | 55.92M | 56.18M | 56.02M | 55.25M | 54.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |